Table 1.

Baseline demographic and disease characteristics

CharacteristicGroup 1, Intermediate Conversion Factor, n=16Group 2, Higher Conversion Factor, n=48Total, n=64
Conversion factor used4 µg every 4 wk for each weekly dose of 250 IU epoetin or 1.1 µg darbepoetin4 µg every 4 wk for each weekly dose of 125 IU epoetin or 0.55 µg darbepoetin
Boys, n (%)11 (69)23 (48)34 (53)
Mean age, yr (range)11.3 (7–16)13.0 (6–17)12.6 (6–17)
 Age 6–11 yr, n (%)9 (56)16 (33)25 (39)
 Age 12–17 yr, n (%)7 (44)32 (67)39 (61)
Mean hemoglobin, g/dl11.3±0.511.3±0.511.1±0.5
Mean weight, kg33±1239±1438±14
Mean height, cm139±18144±17143±17
Mean Z score for height−1.55±1.84−1.78±1.41−1.72±1.51
Mean Kt/V urea1.57±0.381.60±0.411.60±0.40
Vascular access arteriovenous fistula, n (%)13 (81)31 (65)44 (69)
Race, n (%)
 White11 (69)35 (73)46 (72)
 Black1 (6)1 (2)2 (3)
 Asian2 (13)5 (10)7 (11)
 Other2 (13)7 (15)9 (14)
Etiology of CKD, n (%)
 Hereditary nephropathy3 (19)13 (27)16 (25)
 Hypoplastic/dysplastic kidneys2 (13)12 (25)14 (22)
 Obstructive uropathy4 (25)8 (17)12 (19)
 Other GN2 (13)7 (15)9 (14)
 Systemic disease1 (6)6 (13)7 (11)
 Reflux nephropathy0 (0)5 (10)5 (8)
 FSGS3 (19)1 (2)4 (6)
Median years from first dialysis1.5 (1.1–3.4)1.2 (0.5–4.1)1.3 (0.5–3.7)
Median years from first ESA1.8 (1.2–3.7)1.2 (0.5–3.1)1.3 (0.5–3.1)
Median previous ESA dose
 Darbepoetin alfa, µg/wk17.5 (9–25)20.0 (10–20)20.0 (10–20)
 Epoetin alfa/beta, IU/wk4500 (2250–7500)6000 (4000–6000)6000 (3000–6000)
  • Mean values are shown ±1 SD; median values are shown with interquartile range. ESA, erythropoiesis-stimulating agent.